Careers  |  Sign In  |  Register

Dr. Sabari on Biomarkers of Response to Immunotherapy in Advanced NSCLC

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell lung cancer (NSCLC) patients with no known driver mutation. Dr. Sabari says, to date, PD-L1 is the only effective biomarker, with increased PD-L1 being predictive of better patient outcomes. While TMB was initially thought to be a suitable candidate, the CheckMate-227 data indicated TMB is only a prognostic biomarker. In the future, Dr. Sabari hopes to see additional biomarkers discovered to inform better immunotherapeutic treatment.

Learn more by clicking here.

Faculty

D. Ross Camidge, MD, PhD
D. Ross Camidge, MD, PhD

Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus

Erin Schenk, MD, PhD
Erin Schenk, MD, PhD

Assistant Professor, Medicine - Medical Oncology

University of Colorado Cancer Center

Anschutz Medical Campus